Lampalizumab | m-entrepreneurship.com

Product Name :
Lampalizumab

Search keywords :
Lampalizumab

drugId :
null

Target Vo:
Complement factor D

Target Vo Short Name :
CFD

Moa_Name:
Complement factor D inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Genentech Inc

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Geographic Atrophy

Termination Status :
Phase 3 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Enfortumab vedotin-ejfv medchemexpress
Patritumab custom synthesis
Phospho-PLK1 (Thr210) Antibody: Phospho-PLK1 (Thr210) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 68 kDa, targeting to Phospho-PLK1(T210). It can be used for WB,ICC/IF,FC assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts